Core Viewpoint - China Medical Group (08225.HK) reported a total accounts receivable of RMB 128 million as of December 31, 2024, with adequate impairment provisions made according to accounting standards. The receivables primarily stem from the group's regular business operations [1]. Group 1: Accounts Receivable Recovery Efforts - The company has actively pursued the recovery of receivables since the annual report disclosure, implementing targeted strategies based on the debtor's situation [1]. - For receivables from related parties, the company has established a special working mechanism and has successfully recovered a total of RMB 11,086,946 as of November 30, 2025, with legal arbitration initiated for outstanding amounts [1]. - For non-related party receivables, the company has reached agreements with clients who have a good repayment willingness, resulting in additional recoveries of RMB 4,451,430, with ongoing repayment plans in place [1]. Group 2: Measures for Difficult Receivables - For receivables that are more challenging to recover, the company has legally adopted all available measures, including applying to list relevant debtors as dishonest executors, and will closely monitor their asset status for actionable leads [2]. - The company has established an "Accounts Receivable Management Committee" led by the finance department to enhance operational fund quality and has strengthened internal controls from customer credit assessment to payment term management to prevent new risks [2].
中国医疗集团(08225.HK)：已成功收回关联方款项合计1108.69万元